IGKV2D-29 and Dyskinesia: Limited clinical data suggest the possibility that in PD patients with established dyskinesia, one might be able to maintain the anti-Parkinsonian response and reduce dyskinesia by adding an A2A antagonist and lowering the L-DOPA dose, but this remains to be proven.